Ignite Creation Date:
2024-05-06 @ 6:43 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05762744
Status:
TERMINATED
Last Update Posted:
2023-03-10
First Post:
2023-02-23
Brief Title:
Pharmacogenomics of GLP1 Receptor Agonists
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Pharmacogenomics of GLP1 Receptor Agonists
Status:
TERMINATED
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
We concluded that it would not be possible to meet our recruitment targets within the available budget The study was ended when the funding ended
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Healthy volunteers were recruited from the Old Order Amish population in Lancaster County Pennsylvania After providing informed consent research participants were screened for eligibility The clinical trial was designed as a randomized crossover study in which participants underwent two frequently sampled intravenous glucose tolerance tests - one after receiving a subcutaneous injection of saline and one after receiving a subcutaneous injection of rapid-acting exenatide BYETTA The study sought to determine whether genetic variants are associated with the magnitude of the effect of exenatide If an association were identified this would help physicians to predict whether an individual patient is likely to have a large response to the class of diabetes drugs to which exenatide belongs GLP1 receptor agonists
Detailed Description:
Healthy volunteers were recruited from the Old Order Amish population in Lancaster County Pennsylvania After providing informed consent research participants were screened for eligibility The clinical trial was designed as a randomized crossover study in which participants underwent two frequently sampled intravenous glucose tolerance tests FSIGT - one after receiving a subcutaneous injection of saline and one after receiving a subcutaneous injection of rapid-acting exenatide BYETTA Based on data obtained from the FSIGT participants response to exenatide was assessed -- specifically the effect of exenatide to enhance insulin secretion and accelerate metabolism of glucose The study sought to determine whether genetic variants are associated with the magnitude of the effect of exenatide If an association were identified this would help physicians to predict whether an individual patient is likely to have a large response to the class of diabetes drugs to which exenatide belongs GLP1 receptor agonists
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None